Europe’s medical devices industry saw a rise of 13.6% in deal activity during March 2019, when compared with the last 12-month average, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
A total of 25 medical devices industry deals worth $570.24m were announced for the region in March 2019, against the 12-month average of 22 deals.
Of all the deal types, venture financing saw most activity in March 2019 with 12 transactions, representing a 48% share for the region.
In second place was M&A with seven deals, followed by private equity deals with six transactions, respectively capturing a 28% and 24% share of the overall deal activity for the month.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
In terms of value of deals, private equity was the leading category in Europe’s medical devices industry with $352.3m, while venture financing and M&A deals totalled $135.75m and $82.19m, respectively.
Europe medical devices industry deals in March 2019: Top deals
The top five medical devices deals accounted for 92.5% of the overall value during March 2019.
The combined value of the top five medical devices deals stood at $527.44m, against the overall value of $570.24m recorded for the month. The top announced medical devices deal tracked by GlobalData in March 2019 was Eurazeo’s $339.05m private equity deal with Dutch Ophthalmic Research Center International.
In second place was the $76.74m acquisition of Direct Conversion by Varex Imaging and in third place was Cambridge Innovation Capital, IP Group, Johnson & Johnson Innovation – JJDC, RT Ventures and Woodford Patient Capital Trust’s $52.6m venture financing of Inivata.
The $50m venture financing of SNIPR Biome by Life Sciences Partners, The Lundbeck Foundation, NORTHEAST FAMILY OFFICE and Wellington Partners Venture Capital and Digital Health Ventures, MIG Verwaltungs and Santo Venture Capital’s venture financing of Liva Healthcare for $9.05m held fourth and fifth positions, respectively.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.